Becton Dickinson

The kit is designed for the qualitative detection of nucleic acid from SARS-CoV-2 nasal, nasopharyngeal, and oropharyngeal swab samples.

The test, run on the BD Max system, allows hospitals to diagnose SARS-CoV-2 on site and receive results in less than three hours.

The point-of-care test is designed to detect SARS-CoV-2 antibodies in blood, serum, or plasma, with results available within 15 minutes.

The joint submission of the coronavirus assay is part of a long-standing collaboration between the two firms to put BioGX assays on the BD Max system.

In announcing a national emergency on Friday, Trump paraded out executives from the private sector as the administration tries to increase testing capacity

The test is for use with BD's BD Max fully-automated system and processes 24 samples in less than three hours.

BD will supply its diagnostics and informatics products as part of the contract with Fleming Fund to take on AMR in Asia and sub-Saharan Africa.